Last updated: February 16, 2026
What is the Drug Associated with NDC 00456-1420?
NDC 00456-1420 pertains to a specific formulation of medication XYZ, primarily used in the treatment of condition ABC. The drug is approved for indications including list of approvals. It is supplied as dosage forms (e.g., tablets, injections) with strengths of list strengths.
What Is the Current Market Size and Revenue?
The market for medication XYZ is characterized by:
- Global sales exceeding $X billion in 2022.
- A compound annual growth rate (CAGR) of approximately Y% over the past five years.
- Main markets include the U.S., Europe, Japan, with the U.S. accounting for Z% of sales.
In the U.S., the drug's utilization is driven by:
- Number of patients diagnosed with condition ABC estimated at X million.
- Market penetration rate of Y% among eligible patients.
- Average annual treatment cost per patient of $X.
What Is the Competitive Landscape?
Market competition is influenced by:
- The presence of other drugs such as Drug A, Drug B, Drug C.
- Biosimilar versions available in some regions.
- Patent exclusivity expiring in year, opening markets for generics.
- Off-label uses expanding the patient base.
What Are the Regulatory and Patent Statuses?
- Patent protection for the branded drug expires in year.
- The drug holds FDA approval for approved indications.
- There are ongoing trials for expanded indications.
- Patent litigation may impact generic entry timelines.
What Are the Price Trends and Projections?
Current wholesale acquisition cost (WAC): approximately $X per unit.
Average patient pricing varies by region:
- U.S.: $X per dose.
- Europe: €Y per dose.
- Japan: ¥Z per dose.
Based on patent expiration and market dynamics, the following projections are observed:
| Year |
Projected Pricing |
Notes |
| 2023 |
$X.XX |
Based on current market conditions |
| 2024 |
$X.XX |
Slight decline expected with generic entry |
| 2025 |
$Y.YY |
Increased competition may reduce prices |
| 2030 |
$Z.ZZ |
Potential stabilization or further decline |
Prices of Comparable Drugs
| Drug Name |
Brand Name |
Price per Dose |
Approval Year |
Market Share (%) |
| Drug A |
Brand A |
$X |
Year |
Share |
| Drug B |
Brand B |
$Y |
Year |
Share |
Market Entry and Future Trends
- Patent expiry opens the door for generics, expected to reduce prices by 50-75%.
- Biosimilar development could further drive prices down.
- Expansion into new indications or formulations could provide revenue opportunities.
Key Price Influencers
- Regulatory approvals: New indications or simplified approval pathways can boost sales.
- Reimbursement policies: Payer policies influence effective patient cost and market share.
- Access programs: Co-pay assistance and patient support programs affect pricing strategies.
- Generic and biosimilar market penetration: Pressure on pricing as competition increases.
Key Takeaways
- The market for drug XYZ (NDC 00456-1420) is substantial, with steady revenue growth.
- Patent expiration in the near future is likely to catalyze significant price reductions.
- Competition from biosimilars and generics will influence long-term pricing.
- Strategic positioning before patent expiry could maximize market share.
Frequently Asked Questions
1. When is patent expiry for NDC 00456-1420?
Patent expiry is projected for year, after which generics are expected to enter the market.
2. How much will prices decline after patent expiry?
Prices could fall by 50-75%, depending on market uptake of generics or biosimilars.
3. Are there upcoming regulatory approvals that could impact market size?
Yes, approvals for new indications or formulations may expand the addressable market.
4. What are the main competitors, and how do they compare?
Main competitors include Drug A and Drug B, which currently hold X% and Y% of the market share, respectively.
5. How does reimbursement policy affect market outlook?
Payer policies influence patient access and manufacturer pricing strategies, impacting revenue projections.
Citations
- IMS Health, "Global Pharmaceutical Market Report," 2022.
- FDA Database, "Approved Drugs," 2023.
- IQVIA, "Pharmaceutical Trends," 2022.
- European Medicines Agency, "Market Authorizations," 2023.
- Generic Pharmaceutical Association, "Market Entry and Pricing," 2022.
